CORCEPT THERAPEUTICS INC Logo

CORCEPT THERAPEUTICS INC

Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.

CORT | US

Overview

Corporate Details

ISIN(s):
US2183521028
LEI:
Country:
United States of America
Address:
101 REDWOOD SHORES PARKWAY, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of medications that modulate the effects of cortisol. The company's scientific approach centers on regulating cortisol activity at the glucocorticoid receptor (GR) to develop novel treatments for severe disorders. Its lead product, Korlym®, is approved for treating hyperglycemia associated with endogenous Cushing's syndrome. Corcept is advancing a broad clinical pipeline of selective cortisol modulators for a range of diseases across key therapeutic areas, including endocrinology, oncology, metabolism, and neurology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CORCEPT THERAPEUTICS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CORCEPT THERAPEUTICS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CORCEPT THERAPEUTICS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT

Talk to a Data Expert

Have a question? We'll get back to you promptly.